AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Verastem's New Ovarian Cancer Drug Sees Strong Sales, Analysts Predict Significant Upside
ByAinvest
Saturday, Aug 9, 2025 3:08 pm ET1min read
Verastem's (VSTM) new ovarian cancer drug, Avmapki Fakzynja Co-pack, generated $2.1 million in revenue within six weeks of launch, causing a 22% surge in the company's shares. Analysts predict a significant upside for VSTM, with a consensus "Outperform" rating and an average one-year price target of $15.38.
Verastem Oncology (VSTM), a biopharmaceutical company focused on developing new medicines for patients with RAS/MAPK pathway-driven cancers, reported strong financial results for the second quarter of 2025. The company's new drug, Avmapki Fakzynja Co-pack, achieved net product revenue of $2.1 million in the first six weeks of its launch, contributing to a 22% surge in the company's stock price [1].The drug, which is a combination of avutometinib and defactinib, received FDA approval in May 2025 for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. The approval was granted approximately two months in advance of the Prescription Drug User Fee Act (PDUFA) action date of June 30, 2025 [1].
Verastem's stock price surged by 22% following the announcement of the drug's revenue, with analysts predicting a significant upside for the company. Analysts have given VSTM a consensus "Outperform" rating and an average one-year price target of $15.38 [1].
The company's total revenue for the three months ended June 30, 2025, was $2.1 million, compared to $10.0 million for the same period in 2024. Net product revenue for the 2025 quarter was also $2.1 million, compared to $0.0 million for the 2024 quarter [1].
Verastem's stock price surge and the positive financial results reflect the company's strong pipeline and the potential of its new drug, Avmapki Fakzynja Co-pack, in the treatment of ovarian cancer. The company continues to make progress in its clinical trials and has several key milestones expected for the second half of 2025, including reporting the outcome of the IDMC's sample-size re-estimation recommendation for RAMP 301 in Q4 2025 [1].
References:
[1] https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-reports-second-quarter-2025-financial-results
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet